Catalyst MedTech Enhances Partnership, Expands Cardiac Imaging Sales

Boosting Cardiac Imaging: Catalyst MedTech and Arineta Join Forces
Catalyst MedTech is thrilled to announce a significant enhancement of its existing collaboration with Arineta, a key player in the realm of cardiovascular imaging. This expanded partnership includes sales representation of Arineta's renowned SpotLight™ CT systems across the U.S. market.
Strengthening an Existing Relationship
Over the past two years, Catalyst MedTech has been actively involved in the installation, repair, and maintenance of Arineta's innovative cardiac CT systems. This journey has been a testament to the synergy between the two companies. As the partnership intensifies, Catalyst transitions into a dual role, being both a technical and commercial ally. The focus is on supporting Arineta's strategic goals in North America, further reinforcing sales efforts and generating robust business growth.
Leadership Insights
Martin Shirley, the President & CEO of Catalyst MedTech, eloquently stated, "At Catalyst, we don't just maintain technology—we accelerate it. This expanded relationship with Arineta exemplifies how our Propel Program can unlock untapped potential for OEMs. By leveraging our sales expertise, cardiology market knowledge, and nationwide infrastructure, we're helping Arineta energize their commercial efforts and bring their revolutionary technology to more customers, faster."
Arineta’s Vision
Doug Ryan, CEO of Arineta, expressed enthusiasm about the partnership, stating, "Arineta is dedicated to expanding access to lifesaving cardiovascular imaging, and we are excited to extend our partnership with the Catalyst team to accelerate that vision. Catalyst has been a trusted partner in supporting our installation, upgrades, and customer service programs, and we are pleased to utilize them in an expanded capacity throughout the entire customer lifecycle. This strategic move positions us to meet the growing demand for cardiac CT."
Innovative Technologies Driving Market Growth
Arineta's SpotLight™ and SpotLight™ Duo systems offer groundbreaking single-heartbeat cardiac CT angiography technology, setting new benchmarks in cardiovascular imaging. These innovative solutions resonate deeply with Catalyst's commitment to enabling advanced diagnostics in cardiology. The renewed partnership opens new avenues for the adoption of Arineta's technologies, catering to a growing market demand in health systems, imaging centers, and cardiology practices.
Catalyst's dedicated sales organization is all set not just to reinforce existing opportunities but also to galvanize new sales channels. The integration of Arineta’s exceptional imaging products into Catalyst’s sales framework represents a transformative step towards improving patient access to advanced cardiac imaging services.
Propel Partner Program: A Model for Success
The Propel Partner Program stands as a blueprint for expediting growth among OEMs in the U.S. Catalyst MedTech is not only about providing infrastructure but also about harnessing sales momentum and market access. This partnership with Arineta showcases how collaborations within the Propel Program can yield exceptional results and foster progress in diagnostic imaging.
Empowering Partners and Customers
Shirley concluded with a powerful statement, "We see ourselves as the catalyst for progress in diagnostic imaging—delivering value, access, and acceleration for our partners and their customers. This deepening partnership with Arineta is exactly what Propel was designed to do."
Explore More
For more information about Catalyst MedTech's Propel Partner Program or to discover Arineta's advanced cardiac CT solutions, reach out through their respective websites. Catalyst MedTech is a leader in diagnostic imaging solutions, specializing in nuclear medicine, molecular imaging, and CT, while Arineta remains at the forefront of advanced cardiac technology providing unmatched imaging capabilities.
Frequently Asked Questions
What does the expanded partnership between Catalyst MedTech and Arineta entail?
The expanded partnership includes Catalyst MedTech taking on sales representation for Arineta's SpotLight™ CT systems in the U.S. market.
What are the key features of Arineta's SpotLight™ CT systems?
Arineta's SpotLight™ CT systems are characterized by single-heartbeat cardiac CT angiography technology, known for high-resolution and low-dose imaging.
How long has Catalyst MedTech been collaborating with Arineta?
The partnership has been ongoing for over two years, focusing on installation and maintenance of cardiac CT systems.
What is the aim of the Propel Partner Program?
The Propel Partner Program aims to empower OEMs by providing infrastructure, service, and sales momentum to scale faster in the U.S. market.
What opportunities does this partnership create for healthcare providers?
This partnership enhances access to advanced cardiac CT imaging services for healthcare providers, fostering better patient outcomes.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.